Identification of serum anti‑striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers

Abstract

Solid cancers have a poor prognosis, and their morbidity and mortality after surgery is high. Even after radical surgery for esophageal cancer, there have been cases of early postoperative death. The present study therefore aimed to explore new tumor markers that can predict the early postoperative prognosis. To identify antibody markers, serological antigens were identified using recombinant cDNA expression cloning (SEREX). The results identified striatin 4 (STRN4) as the antigen recognized by serum IgG antibodies in patients with esophageal cancer. After performing an amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA), it was revealed that when compared with healthy donors, serum anti-STRN4 antibody (STRN4-Ab) levels were significantly higher not only in patients with esophageal cancer but also to lesser extent, in those with gastric cancer, colorectal cancer, lung cancer and breast cancer. Compared with STRN4-Ab-negative patients with esophageal cancer, STRN4-Ab-positive patients had a poorer postoperative prognosis at early stages, suggesting that STRN4-Abs may be useful for predicting poor early-stage prognoses of patients with esophageal cancer. The positive diagnosis rates of esophageal cancer using the STRN4-Ab marker and conventional markers, including squamous cell carcinoma antigen and p53 antibody alone, were 26.4, 35.2 and 19.1% respectively; a result that increased up to 59.1% by combining all three markers. Serum STRN4-Ab may serve as a novel marker of esophageal cancer.

JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases

“…Our findings highlighted potential biomarkers for stroke including DIDO1, CPSF2, FOXJ2, DNAJC2, ALDOA, FH4, ASXL2, AP3D1, SERPINE1, and TSTD2 [11][12][13][14][15][16][17]. Likewise, we identified LRPAP1, CFL1, WDR1, and striatin 4 as potential markers for digestive tract tumors [18][19][20][21].…”

The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma

“…The reaction mixture was incubated at room temperature for 6-8 h. Subsequently, anti-human IgG-conjugated acceptor beads (2.5 µl of 40 µg/ml) and glutathione-conjugated donor beads (2.5 µl of 40 µg/ml) (PerkinElmer, Inc.) were added followed by incubation for a further 7-28 days at room temperature in the dark. Chemical emission was read on an EnSpire Alpha microplate reader (PerkinElmer, Inc.; http://www.perkinelmer.com/lab-solutions/resources/docs/GDE_ELISA-to-AlphaLISA.pdf) as previously described (5,15,20,21). By subtracting the alpha photon counts of the GST control from those of the GST fusion proteins, specific reactions were calculated.…”

“…By sequencing the isolated cDNA clones, the SEREX method is suitable as for the large-scale screening for tumor antigens. Large-scale SEREX screening has already identified numerous antibodies or antigens, such as trophoblast cell surface antigen 2 (3), solute carrier family 2 member 1 (4), striatin 4 (5), LDL receptor related protein associated protein 1 (6), proprotein convertase subtilisin/kexin type 9 (7), cofilin 1 (CFL1) and β-actin (ACTB) (8). CFL1 can depolymerize F-actin in a pH-dependent manner and is also involved in lung, pancreatic, and gastric cancer invasion and metastasis (9)(10)(11).…”

Cellular Impacts of Striatins and the STRIPAK Complex and Their Roles in the Development and Metastasis in Clinical Cancers (Review)

“…Apart from being a novel poor-prognosis indicator for oesophageal carcinoma patients [ 91 ], cells with reduced STRN4 expression behaved less aggressively compared to the control cells, as reflected by reduced proliferation, invasion and migration [ 86 ]. An upstream oncogenic regulator of STRN3, miR-885-5p, was recently identified and found to facilitate malignant behaviour in oesophageal cancer cells via regulating the STRN3-mediated Hippo cascade [ 92 ].…”